KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Leases (2019 - 2025)

Sarepta Therapeutics has reported Leases over the past 8 years, most recently at $125.5 million for Q4 2025.

  • For Q4 2025, Leases fell 15.38% year-over-year to $125.5 million; the TTM value through Dec 2025 reached $125.5 million, down 15.38%, while the annual FY2025 figure was $125.5 million, 15.38% down from the prior year.
  • Leases for Q4 2025 was $125.5 million at Sarepta Therapeutics, down from $139.2 million in the prior quarter.
  • Over five years, Leases peaked at $148.3 million in Q4 2024 and troughed at $43.0 million in Q3 2022.
  • A 5-year average of $100.6 million and a median of $124.7 million in 2024 define the central range for Leases.
  • Biggest five-year swings in Leases: tumbled 50.38% in 2021 and later surged 210.11% in 2023.
  • Year by year, Leases stood at $45.5 million in 2021, then soared by 42.66% to $65.0 million in 2022, then surged by 100.07% to $130.0 million in 2023, then grew by 14.13% to $148.3 million in 2024, then fell by 15.38% to $125.5 million in 2025.
  • Business Quant data shows Leases for SRPT at $125.5 million in Q4 2025, $139.2 million in Q3 2025, and $143.0 million in Q2 2025.